CORT
A bad day just got a little busier
Corcept Therapeutics is now dealing with a securities class action that says management glossed over repeated FDA warnings about relacorilant’s data package while talking up the drug’s readiness. In plain English: plaintiffs say the company was selling hope while the regulator was waving a giant red flag.
The FDA wasn’t buying it
According to the complaint, the FDA warned Corcept in pre-submission meetings in 2024 and 2025 that the clinical evidence looked thin. Then came the December 31, 2025 Complete Response Letter, where the agency said it couldn’t make a favorable benefit-risk call because the evidence wasn’t strong enough. That’s the kind of regulatory slap that doesn’t just bruise a pipeline—it can shred investor confidence.
Why investors should care
This lawsuit lands on top of a brutal reset in the stock, which the filing says took Corcept from about $70.20 to $34.80 in a single day after the FDA news. Now the company doesn’t just have to answer the regulator; it may also have to defend itself in court, which is never the kind of double feature shareholders buy tickets for.
Big picture
When a biotech story goes from “promising pipeline” to “FDA said nope” to “now there’s a class action,” the market usually stops giving it the benefit of the doubt. Investors will be watching whether Corcept can rebuild the relacorilant case—or whether this becomes a long, expensive cleanup job.